trending Market Intelligence /marketintelligence/en/news-insights/trending/ZWLYCtuWhROW0HpvkH08kw2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

HLS Therapeutics closes C$50M bought deal offering


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


COVID-19 Impact & Recovery: Investment Banking

HLS Therapeutics closes C$50M bought deal offering

HLS Therapeutics Inc. closed its bought deal offering of 3,126,563 common shares priced at C$16 each, including the exercise in full of the underwriters' overallotment option.

Gross proceeds from the offering are about C$50 million. Net proceeds will be used for business development purposes, including acquisitions of companies and products.

Part of the proceeds will also be used to expand the company's pipeline and fund general corporate purposes and working capital.

The common shares were sold under an underwriting deal between HLS and a syndicate of underwriters co-led by GMP Securities LP and Bloom Burton Securities Inc. and including Clarus Securities Inc. and PI Financial Corp.

Toronto-based HLS Therapeutics sells pharmaceutical products in the specialty central nervous system and cardiovascular markets.